Literature DB >> 1595781

Case report: Rhodococcus equi pneumonia in a patient infected by the human immunodeficiency virus.

B M Gray1.   

Abstract

Rhodococcus equi, a facultative intracellular bacterium, is a common cause of pulmonary infection in farm animals, especially foals. Pulmonary and disseminated infection caused by this organism is occasionally seen in humans, especially in patients whose cell-mediated immunity has been altered by glucocorticoids or cytotoxic chemotherapy. Not surprisingly, the organism may cause serious disease in human immunodeficiency virus (HIV)-infected humans whose T cell-dependent immune system has been profoundly suppressed. This report describes an HIV infected patient with Rhodococcus equi pneumonia and reviews nine additional HIV-infected patients. Treatment in humans is not standardized. Studies in foals indicate that erythromycin and rifampin together are the treatment of choice. The patient in this report responded to this treatment briefly before relapsing and dying of the infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1595781     DOI: 10.1097/00000441-199203000-00010

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

1.  Cavitary Rhodococcus equi pneumonia with endobronchial granulomas: report of an unusual case.

Authors:  S A Fidvi; A R Brudnicki; M I Chowdhury; D Beneck
Journal:  Pediatr Radiol       Date:  2002-12-10

2.  Failure of pulmonary clearance of Rhodococcus equi infection in CD4+ T-lymphocyte-deficient transgenic mice.

Authors:  S T Kanaly; S A Hines; G H Palmer
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

3.  Transfer of a CD4+ Th1 cell line to nude mice effects clearance of Rhodococcus equi from the lung.

Authors:  S T Kanaly; S A Hines; G H Palmer
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

4.  Cytokine modulation alters pulmonary clearance of Rhodococcus equi and development of granulomatous pneumonia.

Authors:  S T Kanaly; S A Hines; G H Palmer
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.